Clinical  ||| S:0 E:9 ||| JJ
characteristics  ||| S:9 E:25 ||| NNS
of  ||| S:25 E:28 ||| IN
IgG4-related  ||| S:28 E:41 ||| CD
retroperitoneal  ||| S:41 E:57 ||| JJ
fibrosis  ||| S:57 E:66 ||| NN
To  ||| S:66 E:69 ||| TO
explore  ||| S:69 E:77 ||| VB
the  ||| S:77 E:81 ||| DT
clinical  ||| S:81 E:90 ||| JJ
characteristics  ||| S:90 E:106 ||| NNS
of  ||| S:106 E:109 ||| IN
IgG4-related  ||| S:109 E:122 ||| FW
retroperitoneal  ||| S:122 E:138 ||| FW
fibrosis  ||| S:138 E:147 ||| FW
( ||| S:147 E:148 ||| -LRB-
RPF ||| S:148 E:151 ||| NNP
)  ||| S:151 E:153 ||| -RRB-
in  ||| S:153 E:156 ||| IN
China ||| S:156 E:161 ||| NNP
.  ||| S:161 E:163 ||| .
From  ||| S:163 E:168 ||| IN
December  ||| S:168 E:177 ||| NNP
2010  ||| S:177 E:182 ||| CD
to  ||| S:182 E:185 ||| TO
September  ||| S:185 E:195 ||| NNP
2013 ||| S:195 E:199 ||| CD
,  ||| S:199 E:201 ||| ,
a  ||| S:201 E:203 ||| DT
total  ||| S:203 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
107  ||| S:212 E:216 ||| CD
IgG4-related  ||| S:216 E:229 ||| CD
disease  ||| S:229 E:237 ||| NN
( ||| S:237 E:238 ||| -LRB-
IgG4-RD ||| S:238 E:245 ||| NNP
)  ||| S:245 E:247 ||| -RRB-
patients  ||| S:247 E:256 ||| NNS
were  ||| S:256 E:261 ||| VBD
reviewed  ||| S:261 E:270 ||| VBN
prospectively ||| S:270 E:283 ||| RB
.  ||| S:283 E:285 ||| .
Their  ||| S:285 E:291 ||| PRP$
clinical ||| S:291 E:299 ||| JJ
,  ||| S:299 E:301 ||| ,
laboratory  ||| S:301 E:312 ||| NN
and  ||| S:312 E:316 ||| CC
histopathological  ||| S:316 E:334 ||| JJ
features  ||| S:334 E:343 ||| NNS
were  ||| S:343 E:348 ||| VBD
summarized ||| S:348 E:358 ||| VBN
.  ||| S:358 E:360 ||| .
And  ||| S:360 E:364 ||| CC
the  ||| S:364 E:368 ||| DT
treatment  ||| S:368 E:378 ||| NN
responses  ||| S:378 E:388 ||| NNS
were  ||| S:388 E:393 ||| VBD
analyzed ||| S:393 E:401 ||| VBN
.  ||| S:401 E:403 ||| .
Among  ||| S:403 E:409 ||| IN
them ||| S:409 E:413 ||| PRP
,  ||| S:413 E:415 ||| ,
22  ||| S:415 E:418 ||| CD
RPF  ||| S:418 E:422 ||| NN
cases  ||| S:422 E:428 ||| NNS
were  ||| S:428 E:433 ||| VBD
identified ||| S:433 E:443 ||| VBN
.  ||| S:443 E:445 ||| .
The  ||| S:445 E:449 ||| DT
male-to-female  ||| S:449 E:464 ||| JJ
ratio  ||| S:464 E:470 ||| NN
and  ||| S:470 E:474 ||| CC
age  ||| S:474 E:478 ||| NN
were  ||| S:478 E:483 ||| VBD
4.5 ||| S:483 E:486 ||| CD
:  ||| S:486 E:488 ||| :
1  ||| S:488 E:490 ||| CD
and  ||| S:490 E:494 ||| CC
63  ||| S:494 E:497 ||| CD
Â±  ||| S:497 E:499 ||| CD
11  ||| S:499 E:502 ||| CD
years  ||| S:502 E:508 ||| NNS
respectively ||| S:508 E:520 ||| RB
.  ||| S:520 E:522 ||| .
The  ||| S:522 E:526 ||| DT
follow-up  ||| S:526 E:536 ||| JJ
period  ||| S:536 E:543 ||| NN
was  ||| S:543 E:547 ||| VBD
3-28  ||| S:547 E:552 ||| CD
months ||| S:552 E:558 ||| NNS
.  ||| S:558 E:560 ||| .
The  ||| S:560 E:564 ||| DT
most  ||| S:564 E:569 ||| RBS
common  ||| S:569 E:576 ||| JJ
onset  ||| S:576 E:582 ||| NN
symptom  ||| S:582 E:590 ||| NN
was  ||| S:590 E:594 ||| VBD
low  ||| S:594 E:598 ||| JJ
back  ||| S:598 E:603 ||| JJ
pain  ||| S:603 E:608 ||| NN
( ||| S:608 E:609 ||| -LRB-
55 ||| S:609 E:611 ||| CD
% ||| S:611 E:612 ||| NN
) ||| S:612 E:613 ||| -RRB-
.  ||| S:613 E:615 ||| .
Multiple  ||| S:615 E:624 ||| JJ
organ  ||| S:624 E:630 ||| NN
involvements  ||| S:630 E:643 ||| NNS
were  ||| S:643 E:648 ||| VBD
documented  ||| S:648 E:659 ||| VBN
in  ||| S:659 E:662 ||| IN
20  ||| S:662 E:665 ||| CD
patients  ||| S:665 E:674 ||| NNS
( ||| S:674 E:675 ||| -LRB-
91 ||| S:675 E:677 ||| CD
% ||| S:677 E:678 ||| NN
) ||| S:678 E:679 ||| -RRB-
,  ||| S:679 E:681 ||| ,
including  ||| S:681 E:691 ||| VBG
lymphadenopathy  ||| S:691 E:707 ||| NNS
( ||| S:707 E:708 ||| -LRB-
n  ||| S:708 E:710 ||| CD
=  ||| S:710 E:712 ||| SYM
9 ||| S:712 E:713 ||| CD
) ||| S:713 E:714 ||| -RRB-
,  ||| S:714 E:716 ||| ,
aortitis  ||| S:716 E:725 ||| NNS
( ||| S:725 E:726 ||| -LRB-
n  ||| S:726 E:728 ||| CD
=  ||| S:728 E:730 ||| SYM
8 ||| S:730 E:731 ||| CD
) ||| S:731 E:732 ||| -RRB-
,  ||| S:732 E:734 ||| ,
sialadenitis  ||| S:734 E:747 ||| NNS
( ||| S:747 E:748 ||| -LRB-
n  ||| S:748 E:750 ||| CD
=  ||| S:750 E:752 ||| SYM
7 ||| S:752 E:753 ||| CD
) ||| S:753 E:754 ||| -RRB-
,  ||| S:754 E:756 ||| ,
dacryoadenitis  ||| S:756 E:771 ||| NNS
( ||| S:771 E:772 ||| -LRB-
n  ||| S:772 E:774 ||| CD
=  ||| S:774 E:776 ||| SYM
5 ||| S:776 E:777 ||| CD
)  ||| S:777 E:779 ||| -RRB-
and  ||| S:779 E:783 ||| CC
autoimmune  ||| S:783 E:794 ||| JJ
pancreatitis  ||| S:794 E:807 ||| NNS
( ||| S:807 E:808 ||| -LRB-
n  ||| S:808 E:810 ||| CD
=  ||| S:810 E:812 ||| SYM
4 ||| S:812 E:813 ||| LS
) ||| S:813 E:814 ||| -RRB-
.  ||| S:814 E:816 ||| .
Allergic  ||| S:816 E:825 ||| JJ
histories  ||| S:825 E:835 ||| NN
were  ||| S:835 E:840 ||| VBD
reported  ||| S:840 E:849 ||| VBN
by10  ||| S:849 E:854 ||| CD
subjects  ||| S:854 E:863 ||| NNS
( ||| S:863 E:864 ||| -LRB-
46 ||| S:864 E:866 ||| CD
% ||| S:866 E:867 ||| NN
) ||| S:867 E:868 ||| -RRB-
.  ||| S:868 E:870 ||| .
Eosinophilia  ||| S:870 E:883 ||| NNP
was  ||| S:883 E:887 ||| VBD
present  ||| S:887 E:895 ||| JJ
in  ||| S:895 E:898 ||| IN
6  ||| S:898 E:900 ||| CD
subjects  ||| S:900 E:909 ||| NNS
( ||| S:909 E:910 ||| -LRB-
27 ||| S:910 E:912 ||| CD
% ||| S:912 E:913 ||| NN
) ||| S:913 E:914 ||| -RRB-
.  ||| S:914 E:916 ||| .
Serum  ||| S:916 E:922 ||| NNP
IgG4  ||| S:922 E:927 ||| NNP
levels  ||| S:927 E:934 ||| NNS
were  ||| S:934 E:939 ||| VBD
significantly  ||| S:939 E:953 ||| RB
elevated  ||| S:953 E:962 ||| VBD
in  ||| S:962 E:965 ||| IN
all  ||| S:965 E:969 ||| DT
subjects ||| S:969 E:977 ||| NNS
.  ||| S:977 E:979 ||| .
Serum  ||| S:979 E:985 ||| JJ
total  ||| S:985 E:991 ||| JJ
IgE  ||| S:991 E:995 ||| JJ
level  ||| S:995 E:1001 ||| NN
was  ||| S:1001 E:1005 ||| VBD
elevated  ||| S:1005 E:1014 ||| VBN
in  ||| S:1014 E:1017 ||| IN
12 ||| S:1017 E:1019 ||| CD
/ ||| S:1019 E:1020 ||| CD
13  ||| S:1020 E:1023 ||| CD
tested  ||| S:1023 E:1030 ||| CD
subjects ||| S:1030 E:1038 ||| NNS
.  ||| S:1038 E:1040 ||| .
Tissue  ||| S:1040 E:1047 ||| NN
biopsies  ||| S:1047 E:1056 ||| NNS
of  ||| S:1056 E:1059 ||| IN
12  ||| S:1059 E:1062 ||| CD
subjects  ||| S:1062 E:1071 ||| NNS
revealed  ||| S:1071 E:1080 ||| VBD
massive  ||| S:1080 E:1088 ||| JJ
lymphocytic  ||| S:1088 E:1100 ||| JJ
infiltration  ||| S:1100 E:1113 ||| NN
and  ||| S:1113 E:1117 ||| CC
obvious  ||| S:1117 E:1125 ||| JJ
tissue  ||| S:1125 E:1132 ||| NN
fibrosis ||| S:1132 E:1140 ||| NN
.  ||| S:1140 E:1142 ||| .
Immunohistochemical  ||| S:1142 E:1162 ||| JJ
staining  ||| S:1162 E:1171 ||| NN
showed  ||| S:1171 E:1178 ||| VBD
a  ||| S:1178 E:1180 ||| DT
massive  ||| S:1180 E:1188 ||| JJ
infiltration  ||| S:1188 E:1201 ||| NN
of  ||| S:1201 E:1204 ||| IN
IgG4-positive  ||| S:1204 E:1218 ||| CD
plasma  ||| S:1218 E:1225 ||| JJ
cell ||| S:1225 E:1229 ||| NN
.  ||| S:1229 E:1231 ||| .
Glucocorticoid  ||| S:1231 E:1246 ||| NNP
was  ||| S:1246 E:1250 ||| VBD
administrated  ||| S:1250 E:1264 ||| VBN
in  ||| S:1264 E:1267 ||| IN
all  ||| S:1267 E:1271 ||| DT
subjects ||| S:1271 E:1279 ||| NNS
.  ||| S:1279 E:1281 ||| .
Most  ||| S:1281 E:1286 ||| JJS
subjects  ||| S:1286 E:1295 ||| NNS
received  ||| S:1295 E:1304 ||| VBD
combined  ||| S:1304 E:1313 ||| VBN
therapy  ||| S:1313 E:1321 ||| NN
with  ||| S:1321 E:1326 ||| IN
immunosuppressive  ||| S:1326 E:1344 ||| JJ
agents  ||| S:1344 E:1351 ||| NNS
or  ||| S:1351 E:1354 ||| CC
tamoxifen ||| S:1354 E:1363 ||| NN
.  ||| S:1363 E:1365 ||| .
IgG4-related  ||| S:1365 E:1378 ||| NNP
RPF  ||| S:1378 E:1382 ||| NNP
is  ||| S:1382 E:1385 ||| VBZ
a  ||| S:1385 E:1387 ||| DT
systemic  ||| S:1387 E:1396 ||| JJ
autoimmune  ||| S:1396 E:1407 ||| JJ
disease  ||| S:1407 E:1415 ||| NN
with  ||| S:1415 E:1420 ||| IN
favorable  ||| S:1420 E:1430 ||| JJ
responses  ||| S:1430 E:1440 ||| NNS
to  ||| S:1440 E:1443 ||| TO
the  ||| S:1443 E:1447 ||| DT
treatments  ||| S:1447 E:1458 ||| NNS
of  ||| S:1458 E:1461 ||| IN
glucocorticoid  ||| S:1461 E:1476 ||| NN
and  ||| S:1476 E:1480 ||| CC
immunosuppressive  ||| S:1480 E:1498 ||| JJ
agents ||| S:1498 E:1504 ||| NNS
.  ||| S:1504 E:1506 ||| .
